|
|
Article: Acadia Pharma Lacking Catalysts - Analyst Blog
- Article from:
- Zacks Investment Research - Analyst Blog
- Article date:
- October 1, 2008
- Author:
CopyrightCopyright 2008 Zacks Investment Research. (Hide copyright information)
|
Acadia Pharma Lacking Catalysts - Analyst Blog
Acadia Pharmaceuticals
(
ACAD
) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders. The company currently has one proprietary clinical program with pimavanserin (ACP-103) for treatment-induced dysfunction in Parkinson's disease. Other potential indications with pimavanserin include use as an adjunctive therapy for schizophrenia and for sleep maintenance in patients with insomnia.
After the failure of the ACP-104 program and the lack of partnering interest in pimavanserin for schizophrenia, Acadia's stock has been hit ...